Abivax S.A.
ABVX
87.01
-1.21
-1.37%
Abivax S.A.
US · ABVX
#1658 by market cap
Listed 2023
87.01
-1.21
-1.37%
Live - 5344 symbols - heartbeat 324s ago
· 2026-10-08 07:00
Pre-market
85.90
-1.28%
After-hours
87.43
+0.48%
Overnight
86.04
-1.11%
- Market cap
- 7.59B
- P/E (TTM)i
- -14.58
- P/Bi
- 18.52
- EPSi
- -5.41
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on ABVX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 815.00K | 2.00K | 1.65M | -- | -- | -- | -- | -- |
| Gross profit | -15.36M | -28.19M | -33.78M | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.30M | 4.89M | 5.60M | 5.58M | 7.49M | 28.82M | 38.90M | 72.87M |
| Research & development | -- | -- | -- | 47.78M | 48.30M | 103.18M | 146.53M | 177.76M |
| Operating profit | -19.11M | -33.30M | -38.01M | -41.40M | -51.21M | -127.38M | -172.98M | -246.06M |
| Pretax profit | -19.80M | -34.89M | -40.13M | -42.45M | -60.74M | -147.74M | -176.24M | -330.25M |
| Tax | -3.97M | -4.26M | -2.58M | 0 | 0 | 0 | 0 | 5.85M |
| Net profit | -15.83M | -30.63M | -37.55M | -42.45M | -60.74M | -147.74M | -176.24M | -336.10M |
| Basic EPS | -2 | -3 | -3 | -3 | -3 | -3 | -3 | -5 |
| Diluted EPS | -1.55 | -2.51 | -2.62 | -2.75 | -3.18 | -3.43 | -2.80 | -4.83 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.89M | 8.94M | 27.34M | 27.69M | 8.03M | 26.98M |
| Research & development | 39.30M | 38.65M | 55.42M | 44.40M | 49.54M | 58.34M |
| Operating profit | -47.20M | -46.50M | -80.71M | -71.65M | -56.23M | -84.11M |
| Pretax profit | -52.37M | -48.41M | -153.36M | -76.11M | -48.24M | -123.51M |
| Tax | 0 | 0 | 0 | 5.85M | 228.00K | -6.08M |
| Net profit | -52.37M | -48.41M | -153.36M | -81.96M | -48.47M | -117.43M |
| Basic EPS | -1 | -1 | -2 | -1 | -1 | -1 |
| Diluted EPS | -0.83 | -0.76 | -2.10 | -1.02 | -0.61 | -1.47 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 20.98M | 18.24M | 37.67M | 75.49M | 36.18M | 285.97M | 170.67M | 551.24M |
| Cash & ST investments | 13.00M | 9.77M | 29.30M | 60.70M | 26.95M | 260.99M | 144.22M | 530.38M |
| Inventory | -- | -- | 0 | -- | -- | -- | -- | -- |
| Total assets | 54.05M | 51.73M | 71.30M | 109.23M | 75.54M | 327.06M | 205.23M | 584.34M |
| Total current liabilities | 8.49M | 12.39M | 19.41M | 32.26M | 51.46M | 88.12M | 92.83M | 63.02M |
| Short-term debt | -- | -- | 12.00K | 10.23M | 30.03M | 31.26M | 43.77M | 1.30M |
| Long-term debt | 10.90M | 20.74M | 33.98M | 34.61M | 8.29M | 26.62M | 52.16M | -- |
| Total liabilities | 19,394,000.00 | 33,136,000.00 | 53,398,000.00 | 83,297,000.00 | 68,355,000.00 | 131,052,000.00 | 164,644,000.00 | 129,136,000.00 |
| Total equity | 34.65M | 18.59M | 17.90M | 25.93M | 7.19M | 196.01M | 40.58M | 455.21M |
| Retained earnings | -62.40M | -93.03M | -37.55M | -81.81M | -143.51M | -282.95M | -438.88M | -738.48M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 132.67M | 86.10M | 619.30M | 551.24M | 513.22M | 427.62M |
| Cash & ST investments | 103.58M | 60.95M | 589.70M | 530.38M | 491.55M | 410.68M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 166.94M | 119.64M | 652.05M | 584.34M | 547.14M | 462.21M |
| Total current liabilities | 105.74M | 112.35M | 78.76M | 63.02M | 62.23M | 71.69M |
| Short-term debt | 44.36M | 48.84M | 29.40M | 1.30M | 1.10M | 1.08M |
| Long-term debt | 47.00M | 34.78M | 15.88M | -- | -- | -- |
| Total liabilities | 173,532,000.00 | 167,921,000.00 | 140,814,000.00 | 129,136,000.00 | 117,548,000.00 | 95,942,000.00 |
| Total equity | -6.59M | -48.28M | 511.24M | 455.21M | 429.59M | 366.27M |
| Retained earnings | -486.52M | -528.60M | -669.81M | -738.48M | -764.31M | -864.96M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -14.60M | -27.47M | -29.82M | -45.05M | -53.94M | -97.13M | -154.07M | -161.13M |
| Depreciation & amortization | 71.00K | 80.00K | 66.00K | 302.00K | 485.00K | 707.00K | 1.10M | 1.07M |
| Free cash flow | -15.37M | -28.41M | -30.72M | -45.10M | -54.26M | -97.40M | -154.72M | -161.27M |
| Dividends paid | -- | -- | -- | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -- | 13.67M | 26.40M | 69.68M | 46.37M | 353.39M | 434.00K | 648.12M |
| Ending cash balance | 13.00M | 9.77M | 29.30M | 60.70M | 26.95M | 251.94M | 144.22M | 516.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -33.28M | -33.34M | -71.28M | -23.23M | -50.52M | -51.99M |
| Depreciation & amortization | 273.00K | 251.00K | 272.00K | 276.00K | 367.00K | 374.00K |
| Free cash flow | -33.32M | -33.36M | -71.28M | -23.32M | -50.57M | -52.10M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock buybacks / issuance | -- | -- | -- | 40.04M | -- | -- |
| Ending cash balance | 103.58M | 60.95M | 589.70M | 516.69M | 477.42M | 387.99M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -38.20 | -115.06 | -205.80 | -154.57 | -315.24 | -144.34 | -148.98 | -135.58 |
| ROA %i | -29.34 | -57.92 | -61.05 | -45.53 | -76.04 | -73.79 | -66.22 | -85.14 |
| ROIC %i | -33.00 | -68.92 | -78.08 | -54.73 | -92.46 | -89.27 | -88.73 | -107.24 |
| 5-year avg ROE %i | -25.41 | -45.43 | -80.55 | -114.83 | -183.91 | -205.35 | -212.13 | -198.09 |
| EBIT margin %i | -106,105.56 | -144,800.00 | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.47 | 1.47 | 1.94 | 2.34 | 0.70 | 3.25 | 1.84 | 8.75 |
| Quick ratioi | 2.45 | 1.45 | 1.92 | 2.14 | 0.69 | 3.18 | 1.72 | 8.58 |
| Debt / assetsi | 20.17 | 40.10 | 47.68 | 41.09 | 51.84 | 17.75 | 47.44 | 0.32 |
| LT debt / equityi | 31.45 | 111.57 | 189.84 | 133.61 | 126.96 | 13.66 | 132.05 | 0.12 |
| Interest coveragei | -40.72 | -21.00 | -18.46 | -13.46 | -19.11 | -9.69 | -13.18 | -10.60 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -57.41 | -135.58 | -157.07 | -252.35 |
| ROA %i | -111.27 | -163.31 | -45.01 | -85.14 | -93.04 | -137.91 |
| ROIC %i | -- | -- | -51.24 | -107.24 | -122.40 | -190.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.25 | 0.77 | 7.86 | 8.75 | 8.25 | 5.97 |
| Quick ratioi | 1.16 | 0.67 | 7.74 | 8.58 | 8.07 | 5.90 |
| Debt / assetsi | 55.44 | 70.69 | 7.04 | 0.32 | 0.26 | 0.26 |
| LT debt / equityi | -- | -- | 3.23 | 0.12 | 0.08 | 0.04 |
| Interest coveragei | -11.77 | -12.73 | -19.03 | -10.60 | -11.31 | -15.93 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research & Development (R&D) of pharmaceutical products in order to market them in the future100.00%
Region
France100.00%
Quote time 2026-10-08 07:00:07 · For reference only, not investment advice and not tailored to your situation.